These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers. Singh K, Tantravahi U, Lomme MM, Pasquariello T, Steinhoff M, Sung CJ. Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259 [Abstract] [Full Text] [Related]
4. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups. Woo JW, Lee K, Chung YR, Jang MH, Ahn S, Park SY. Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910 [Abstract] [Full Text] [Related]
5. Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines. Press MF, Seoane JA, Curtis C, Quinaux E, Guzman R, Sauter G, Eiermann W, Mackey JR, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Bee V, Ma Y, Villalobos I, Slamon DJ. JAMA Oncol; 2019 Mar 01; 5(3):366-375. PubMed ID: 30520947 [Abstract] [Full Text] [Related]
7. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline. Fan YS, Casas CE, Peng J, Watkins M, Fan L, Chapman J, Ikpatt OF, Gomez C, Zhao W, Reis IM. Breast Cancer Res Treat; 2016 Feb 01; 155(3):457-62. PubMed ID: 26895325 [Abstract] [Full Text] [Related]
8. Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer. Guo L, Yuan P, Zhang J, Ling Y, Li W, Zhao B, Ying J, Xuan L. Breast Cancer Res Treat; 2017 Nov 01; 166(1):77-84. PubMed ID: 28712009 [Abstract] [Full Text] [Related]
10. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience. Varga Z, Noske A. PLoS One; 2015 Nov 01; 10(10):e0140652. PubMed ID: 26473483 [Abstract] [Full Text] [Related]
18. Implementation of the 2018 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2/neu Assessment by FISH in breast cancers: predicted impact in a single institutional cohort. Zare S, Rong J, Daehne S, Roma A, Hasteh F, Dell'Aquila M, Fadare O. Mod Pathol; 2019 Nov 01; 32(11):1566-1573. PubMed ID: 31190000 [Abstract] [Full Text] [Related]
19. Laboratory compliance with the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 testing guidelines: a 3-year comparison of validation procedures. Dyhdalo KS, Fitzgibbons PL, Goldsmith JD, Souers RJ, Nakhleh RE. Arch Pathol Lab Med; 2014 Jul 01; 138(7):876-84. PubMed ID: 24978913 [Abstract] [Full Text] [Related]